Abstract
Interventions to reduce the likelihood of relapse, or a return to substance abuse after a period of abstinence, are important components of substance abuse treatment. Treatment interventions for adolescence with substance use disorders should incorporate principles of relapse prevention. The relapse prevention model advanced by Marlatt and Gordon and others in the addiction field is a self-control model, based on a cognitive-behavioral approach. This model stands in contrast to a disease model, which many in the medical field have adhered to. This paper presents a summary of the key features of Marlatt and Gordons cognitive-behavioral approach to relapse prevention.
Keywords: Alcohol use disorders, treatment, substance use disorders, Interventions, relapse, abstinence, relapse prevention, addiction, self-control, cognitive-behavioral
Adolescent Psychiatry
Title: Relapse Prevention
Volume: 1 Issue: 2
Author(s): Richard Rosner
Affiliation:
Keywords: Alcohol use disorders, treatment, substance use disorders, Interventions, relapse, abstinence, relapse prevention, addiction, self-control, cognitive-behavioral
Abstract: Interventions to reduce the likelihood of relapse, or a return to substance abuse after a period of abstinence, are important components of substance abuse treatment. Treatment interventions for adolescence with substance use disorders should incorporate principles of relapse prevention. The relapse prevention model advanced by Marlatt and Gordon and others in the addiction field is a self-control model, based on a cognitive-behavioral approach. This model stands in contrast to a disease model, which many in the medical field have adhered to. This paper presents a summary of the key features of Marlatt and Gordons cognitive-behavioral approach to relapse prevention.
Export Options
About this article
Cite this article as:
Rosner Richard, Relapse Prevention, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020131
DOI https://dx.doi.org/10.2174/2210676611101020131 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Current Pharmaceutical Design Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice
Letters in Drug Design & Discovery School-based Prevention for Adolescent Internet Addiction: Prevention is the Key. A Systematic Literature Review
Current Neuropharmacology A Review Article About Some Herbs Affecting Vitiligo Based on Avicenna’s Canon
Current Drug Discovery Technologies Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Coffee, Caffeine and Cognition: a Benefit or Disadvantage?
Letters in Drug Design & Discovery Supervised Disulfiram as Adjunct to Psychotherapy in Alcoholism Treatment
Current Pharmaceutical Design Editorial [Hot Topic: The Medicinal Chemistry of Agents Targeting the Endogenous Cannabinoid System (Guest Editor: Outi M. H. Salo-Ahen)]
Current Topics in Medicinal Chemistry BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease
Current Alzheimer Research The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Machine Learning and Molecular Dynamics Based Insights into Mode of Actions of Insulin Degrading Enzyme Modulators
Combinatorial Chemistry & High Throughput Screening Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation
CNS & Neurological Disorders - Drug Targets Stress, the Autonomic Nervous System, and the Immune-kynurenine Pathway in the Etiology of Depression
Current Neuropharmacology Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Machine Learning Methods in Precision Medicine Targeting Epigenetic Diseases
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Alzheimer’s Disease Amyloid Peptides Interact with DNA, As Proved by Surface Plasmon Resonance
Current Alzheimer Research Homochiral Drug Design and Development by Racemization
Combinatorial Chemistry & High Throughput Screening